Prostate Cancer Drug Development Summit

Memo

The inaugural virtual Prostate Cancer Drug Development Summit lands at a crucial time as the first and only dedicated conference for large pharma, biotech and pioneering academics to unite under a common and ambitious goal of accelerating the practical discovery, translation, and clinical development of safe and effective treatments for prostate cancer. Devised with three crucial and bold intentions, this meeting will enable you too:1. Overcome the key biological obstacles constraining truly successful prostate cancer therapies2. Discuss novel, cutting edge targeted therapies for prostate cancer3. Bring together key stockholders within the prostate cancer drug development field with the common aim of bringing-to-market safe, efficient treatments to patients-in-need Here's a sneak peek of crucial topics to be addressed:* Role of immunotherapy for treatment of prostate cancer* Bringing theranostics to prostate cancer* Optimizing strategies for overcoming the immunosuppressive prostate tumor microenvironment* Assessing opportunities and challenges for T-cell directed therapies in prostate cancer* Examining next-generation small molecule inhibitors, degraders of androgen receptor (AR) and AR-splice variants Join 60+ thought-leaders converging at the first industry-led Prostate Cancer Drug Development Summit to gain the latest scientific insights with renowned Urologists/Oncologists and those striving to advance safe and effective therapeutic breakthroughs to patients in need. URLs:Tickets: https://go.evvnt.com/757702-2?pid=5569Brochure: https://go.evvnt.com/757702-3?pid=5569 Prices:Industry: Conference + 2 Workshops: USD 2697.0,Industry: Conference + 1 Workshop: USD 2348.0,Industry: Conference Only: USD 1999.0,Academic: Conference + 2 Workshops: USD 2397.0,Academic: Conference + 1 Workshop: USD 2098.0,Academic: Conference Only: USD 1799.0,Solution Provider: Conference + 2 Workshops: USD 3297.0,Solution Provider: Conference + 1 Workshop: USD 2898.0,Solution Provider: Conference Only: USD 2499.0 Speakers: Ellen Filvaroff, Bristol-Myers Squibb, Vivek Arora, Bristol Myers Squibb, Alison Crawford, Regeneron Pharmaceuticals, Inc, Maggie Janat-Amsbury, Amgen, Andrew Cavey, Novartis/Advanced Accelerator Applications, Yifah Yaron, Harpoon Therapeutics, Eric Campeau, Zenith Epigenetics, Colin Hayward, Telix Pharmaceuticals, Alessandra Cesano, ESSA Pharmaceuticals, Ronan LeMoigne, ESSA Pharmaceuticals, Graham Kelly, Noxopharm, Robert Getzenberg, Veru Pharma, Andreas Pahl, Heidelberg Pharma, Julia Coronella, Poseida Therapeutics, Ramesh Narayanan, University of Tennessee Health Science Center, Oliver Sartor, Tulane Cancer Center and Bernadine Laborde Professor of Cancer Research, Ana Aparicio, University of Texas, MD Anderson Cancer Center, Patrick Pilie, MD Anderson Cancer Center, Ben Tran, Peter MacCallum Cancer Centre, Himisha Beltran, Harvard Medical School, Ravi Madan, NIC/NIH, Sumit Subudhi, University of Texas, MD Anderson Cancer Center, Feng Yang, Baylor College of Medicine Houston, Michael Haffner, Fred Hutchinson Cancer Research Center, Frank Lin, NCI/NIH, John Lee, Fred Hutchinson Cancer Research Center, Daniel Harrington, The University of Texas Health Science Center at Houston, Henry Long, Dana-Farber Cancer Institute Date and Time: On Tuesday August 17, 2021 at 9:00 am (ends Thursday August 19, 2021 at 5:00 pm)